Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.24.00176 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Kelly-Anne Phillips und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Genes, BRCA1. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers. METHODS Using pooled observational data from four prospective cohort studies, associations between hormonal contraceptive use and BC risk for unaffected female BRCA1 and BRCA2 mutation carriers were assessed using Cox regression. RESULTS Of 3,882 BRCA1 and 1,509 BRCA2 mutation carriers, 53% and 71%, respectively, had ever used hormonal contraceptives for at least 1 year (median cumulative duration of use, 4.8 and 5.7 years, respectively). Overall, 488 BRCA1 and 191 BRCA2 mutation carriers developed BC during median follow-up of 5.9 and 5.6 years, respectively. Although for BRCA1 mutation carriers, neither current nor past use of hormonal contraceptives for at least 1 year was statistically significantly associated with BC risk (hazard ratio [HR], 1.40 [95% CI, 0.94 to 2.08], P = .10 for current use; 1.16 [0.80 to 1.69], P = .4, 1.40 [0.99 to 1.97], P = .05, and 1.27 [0.98 to 1.63], P = .07 for past use 1-5, 6-10, and >10 years before, respectively), ever use was associated with increased risk (HR, 1.29 [95% CI, 1.04 to 1.60], P = .02). Furthermore, BC risk increased with longer cumulative duration of use, with an estimated proportional increase in risk of 3% (1%-5%, P = .002) for each additional year of use. For BRCA2 mutation carriers, there was no evidence that current or ever use was associated with increased BC risk (HR, 0.70 [95% CI, 0.33 to 1.47], P = .3 and 1.07 [0.73 to 1.57], P = .7, respectively). CONCLUSION Hormonal contraceptives were associated with increased BC risk for BRCA1 mutation carriers, especially if used for longer durations. Decisions about their use in women with BRCA1 mutations should carefully weigh the risks and benefits for each individual.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
- Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
- Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
- Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA.
ORCID-Profile: Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek, Mary Beth Terry, James A Chamberlain, Julie K Bassett, Amber M Aeilts, Irene L Andrulis, Saundra S Buys, Wanda Cui, William D Foulkes, Michael L Friedlander, John L Hopper, Esther M John, Beth Y Karlan, Raymond H Kim, Allison W Kurian, Jan Lubinski, Kelly Metcalfe, Katherine L Nathanson, Christian F Singer, Melissa C Southey, Nadine Tung, Steven A Narod, Roger L Milne
Förderung
- NCI NIH HHS
Zitieren
APA
Phillips, K. A., Kotsopoulos, J., Domchek, S. M., Terry, M. B., Chamberlain, J. A., Bassett, J. K., Aeilts, A. M., Andrulis, I. L., Buys, S. S., Cui, W., Daly, M. B., Eisen, A. F., Foulkes, W. D., Friedlander, M. L., Gronwald, J., Hopper, J. L., John, E. M., Karlan, B. Y., Kim, R. H., …, & Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the… (2025). Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00176
Vancouver
Phillips KA, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00176
BibTeX
@article{Phillips2025,
author = {Phillips, Kelly-Anne and Kotsopoulos, Joanne and Domchek, Susan M and Terry, Mary Beth and Chamberlain, James A and Bassett, Julie K and Aeilts, Amber M and Andrulis, Irene L and Buys, Saundra S and Cui, Wanda and Daly, Mary B and Eisen, Andrea F and Foulkes, William D and Friedlander, Michael L and Gronwald, Jacek and Hopper, John L and John, Esther M and Karlan, Beth Y and Kim, Raymond H and Kurian, Allison W and Lubinski, Jan and Metcalfe, Kelly and Nathanson, Katherine L and Singer, Christian F and Southey, Melissa C and Symecko, Heather and Tung, Nadine and Narod, Steven A and Milne, Roger L and Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the…, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the… and Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the…, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study, the…},
title = {Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.24.00176}
}
EUVIMED